Detection of Lung Cancer Cases in Chest CT Scans Utilizing Artificial Intelligence: A Retrospective Analysis of Data During the COVID-19 Pandemic - Zukov, R.A; Safontsev, I.P.; Klimenok, M.P; Zabrodskaya, T.E.; Merkulova, N.A.; Chernina, V.Yu; Belyaev, M.G.; Goncharov, M.Yu; Omelyanovsky, V.V.; Ulyanova, K.A.; Soboleva, E.A.; Donskova, M.A; et al. (medRxiv, 2023)
Purpose To evaluate the potential of using artificial intelligence (AI) focused pulmonary nodule search on chest CT data obtained during the COVID-19 pandemic to identify lung cancer (LC) patients.Methods A multicenter, retrospective study in the Krasnoyarsk region, Russia analyzed CTs of COVID-19 patients using the automated algorithm, Chest-IRA by IRA Labs. Pulmonary nodules larger than 100 mm³ were identified by the AI and assessed by four radiologists, who categorized them into three groups: “high probability of LC”, “insufficiently convincing evidence of LC”, “without evidence of LC”. Patients with findings were analyzed by radiologists, checked with the state cancer registry and electronic medical records. Patients with confirmed findings that were not available in the cancer registry were invited for chest CT and verification was performed according to the decision of the medical consilium. The study also estimated the economic impact of the AI by considering labor costs and savings on treatment for patients in the early stages compared to late stages, taking into account the saved life years and their potential contribution to the gross regional product.Results An AI identified lung nodules in 484 out of 10,500 chest CTs. Of the 484, 355 could be evaluated, the remaining 129 had de-anonymization problems and were excluded. Of the 355, 252 cases having high and intermediate probabilities of LC, 103 were found to be false positives. From 252 was 100 histologically verified LC cases, 35 were in stages I-II and 65 were in stages III-IV. 2 lung cancers were diagnosed for the first time. Using AI instead of CT review by radiologists will save 2.43 million rubles (23,786 EUR/ 26690 USD/ 196,536 CNY) in direct salary, with expected savings to the regional budget of 8.22 million rubles (80,463 EUR/ 90,466 USD/ 666,162 CNY). The financial equivalent of the life years saved was 173.25 million rubles (1,695,892 EUR/ 1905750 USD/ 14,033,250 CNY). The total effect over five years is estimated at 183.9 million rubles (1,800,142 EUR/ 2,022,907 USD/ 14,895,949 CNY).Conclusion Using AI to evaluate large volumes of chest CTs done for reasons unrelated to lung cancer screening may facilitate early and cost-effective detection of incidental pulmonary nodules that might otherwise be missed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Federal State Budgetary Educational Institution of Higher Education Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Healthcare of the Russian Federation gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.AIartificial intelligenceCTcomputer tomographyGRPgross regional productLDCTlow dose computed tomographyLClung cancerNLSTNational Lung Screening TrialKKCODKrasnoyarsk Krai Clinical Oncologic Dispensary named after A.I. KryzhanovskyQALYsquality-adjusted life yearsROC AUCreceiver operating characteristic area under the curveSWOTstrengths, weaknesses, opportunities, threats